Carl June: A "living drug" that could change the way we treat cancer
卡爾·朱恩: 「活體藥」開啓腫瘤治療新方式
Carl June is a renowned pioneer in the fight against cancer. Full bio
Double-click the English transcript below to play the video.
I've told this story in public,
baseball player who said,
尤奇貝拉曾說,
in the road, take it."
for more than a century,
用免疫系統對抗腫瘤的方法,
as a way to fight cancer,
unfortunately, been disappointing.
caused by viruses,
gave up on the idea
to fight cancer.
did not evolve to fight cancer;
從來不是對付腫瘤,
invading from the outside.
bacteria and viruses.
has trouble with most cancers
from the outside;
not recognize the cancer as a problem,
識別不出腫瘤細胞,
and also our normal cells,
like colitis or multiple sclerosis.
例如結腸炎或多發性硬化症。
synthetic immune systems
and kill cancer cells.
a synthetic immune system.
and synthetic biology.
與合成生物學來實現。
parts of the immune system,
cells infected with viruses,
被病毒侵染的細胞,
antibodies that are secreted
殺死細菌的抗體。
these two functions
to repurpose them to fight cancer?
腫瘤的人工細胞,要怎麼做呢?
to insert the genes for antibodies
可以把 B 細胞中的抗體基因
as a Trojan horse
from Greek mythology,
融合了獅頭、羊身、蛇尾,
and a serpent's tail.
thing that we had created
our T cells carrier
Receptor T cells," or CAR T cells.
也叫 CAR T細胞。
激活 T 細胞消滅功能的基因。
into their killing mode.
into somebody with cancer,
see and bind to their tumor target?
T cells on steroids.
buildup system in the body
and multiply by the millions,
are the first living drug in medicine.
是首種「活體藥」。
and then you have to take them again --
然後必須再次攝取。
and on the job for years.
保持活性的時間長達數年,
in the bodies of our cancer patients
體內的 CAR T 細胞
cancer T cells, CAR T cells,
of more than 17 years.
for the rest of your life.
of a new paradigm in medicine.
to these T-cell infusions.
其中一個重大挑戰是:
that will work in a patient
an identical twin.
the patient's own T cells.
患者的自體 T 細胞。
platform for this in the 1990s.
搭建了一個很厲害的平臺。
CAR T cells in patients
對晚期愛滋病患者
survived in the patients
and decreased their viruses,
減少了體內病毒,
and over the next decade
CAR T 細胞的設計。
to the CAR T cell design.
leukemia patients.
lymphocytic leukemia in 2012.
every year in the United States.
was a retired Marine sergeant
for his funeral.
and within days, he had high fevers.
他出現了高燒,
and was comatose.
fork in the road happened.
the CAR T cell infusion,
had been there had melted.
no evidence of leukemia,
three patients we treated,
now for eight years,
至今已達八年,
the leukemia in these patients
and 7.7 pounds of tumor in each patient.
2.9 到 7.7 磅的腫瘤。
bioreactors for these CAR T cells,
提供了絕佳的環境,
and millions of CAR T cells
blood and tumor masses.
can punch far above their weight class,
會使用「拳擊技巧」
1,000 tumor cells.
能殺死一千個腫瘤細胞,
of one to a thousand.
its daughter progeny cells
and divide in the body
in cancer medicine.
who had full remission
who had run out of options,
(一部反應醫療困境的文學作品)
for those forks in the road.
to treat children with acute leukemia,
on the trial was Emily Whitehead,
a series of chemotherapy
over several years,
was advanced, incurable leukemia.
不可治癒的白血病。
her liver, her spleen.
with the CAR T cells
she did not get better.
officer had in 2010,
in the whole road of this story.
and on life support
依靠呼吸機維持生命,
as 106 degrees Fahrenheit for three days.
what was causing those fevers.
blood tests for infections,
血液感染物檢查,
an infectious cause for her fever.
very unusual in her blood
before in medicine.
called interleukin-6, or IL-6,
above the normal levels.
fork in the road came in.
of pediatric arthritis.
兒童特發性關節炎。
following as a cancer doc,
for arthritis for my daughter,
before Emily was admitted to the hospital,
that my daughter had.
to the pharmacy at Emily's hospital,
these very high levels of IL-6,
高間白素 -6 含量時,
with this arthritis drug?"
for suggesting that.
to the institutional review board,
和她的父母的批准,
short of striking.
with tocilizumab,
and still in remission.
of the high fevers and coma,
出現的發熱和昏迷反應
all patients who respond to the therapy.
大多出現了這些症狀,
in those patients who fail to respond.
for these high fevers after therapy,
出現這些症狀,
"the worst flu in their life,"
of the twisting and turning path
are often those who are not cured.
病情通常不會好轉。
清除白血病腫瘤之間
to eradicate leukemia.
CAR T cells for leukemia,
CAR T 細胞療法的同時,
of tocilizumab to block the IL-6 effects
以及 CRS 症狀。
in these patients.
in medical history.
completed further trials
the first 30 we treated,
in patients with advanced cancer
癌症研究中聞所未聞。
success in a cancer trial
患者完全起作用,
had a complete response rate.
"New England Journal of Medicine" in 2013.
發表了一篇出色的相關研究,
has since confirmed those results.
leukemia in August of 2017.
用該療法治療小兒和青少年白血病。
of a cell and gene therapy,
has also been tested now
a year in the United States.
and have been durable to date.
the therapy of this advanced lymphoma
CAR T 細胞療法。
and scientists around the world
with the rapid pace of advancement.
who were formerly terminal
那些原本已至絕路的患者
就像艾美莉那樣。
that may, in fact, be a cure.
而這有可能意味著徹底治癒。
about the financial cost.
to make the CAR T cells for each patient.
病人要花上十五萬美元。
of treating CRS and other complications,
和其它併發症的費用,
one million dollars per patient.
of failure, though, is even worse.
若療法失敗,費用更高。
for cancer are also expensive
同樣費用高昂,
research done now
to all patients.
and evolving field,
therapies and services,
to do things more efficiently.
all the forks in the road
as very important.
of this magnitude don't happen overnight.
不是一蹴而就的,
after a 30-year journey,
走過 30 年才得以問世,
and surprises.
vision and patience
is not always a dilemma or a detour;
we may not know it at the time,
ABOUT THE SPEAKER
Carl June - Oncologist, researcher, professorCarl June is a renowned pioneer in the fight against cancer.
Why you should listen
Carl June's revolutionary leukemia therapy, which was recently approved by the FDA, uses genetically engineered versions of a patient’s own T cells and is the first personalized cell therapy for cancer to be sanctioned in America. Developed by June and his colleagues, this method has the potential to help patients with many other types of cancers.
June is currently Director of the Center for Cellular Immunotherapies at the Perelman School of Medicine and Director of the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania. A graduate of the Naval Academy in Annapolis and Baylor College of Medicine, he has published more than 350 manuscripts and is the recipient of numerous prizes and honors, including election to the Institute of Medicine in 2012 and the American Academy of Arts and Sciences in 2014, as well as being named one of TIME Magazine's 100 Most Influential People in 2018.
Carl June | Speaker | TED.com